Is what Acadia Pharmaceutical CEO Uli Hacksell said he was receiving from the current phase 2 ADP (Alzheimer's Disease Psychosis) trial, during the recent Oppenheimer Healthcare conference on December 10th. He mentioned in addition to the anti-psychotic and sleep benefit from Pimavanserin, there were other potential benefits that Pimavanserin could provide for Alzheimer's patients; such as agitation, anxiety, aggression, and cognition. Regarding cognition, the CEO believes that Pimavanserin may not increase cognitive loss at the same rate that current Atypical Antipsychotics do.
There has been much mentioned over time about cognition from the CEO and others at Acadia as it pertains to Alzheimer's patients. The current standard of care involves a group known as cholinergic drugs. The list of current cholinergic drugs approved for cognition/maintenance in Alzheimer's patients are listed below.
Aricept (donepezil) - Approved for all stages of Alzheimer's.
Exelon - Approved to treat mild to moderate Alzheimer's.
Razadyn - Approved to treat mild to moderate Alzheimer's.
Namenda - Approved for moderate to severe Alzheimer's.
Acadia stated that Pimavanserin used with cholinergic drugs has been shown to increase cognition in pre-clinical animal trials. If it proves out in the current ADP trial, that Alzheimers patients taking Pimavanserin with their cholinergic drug, do not lose cognition at the rate seen with current antipsychotics, then it will be another improvement, alongside other safety factors that Pimavanserin has shown. The read-out from the ADP trial will be around the fourth quarter of 2015. Thank you for reading.
There has been much mentioned over time about cognition from the CEO and others at Acadia as it pertains to Alzheimer's patients. The current standard of care involves a group known as cholinergic drugs. The list of current cholinergic drugs approved for cognition/maintenance in Alzheimer's patients are listed below.
Aricept (donepezil) - Approved for all stages of Alzheimer's.
Exelon - Approved to treat mild to moderate Alzheimer's.
Razadyn - Approved to treat mild to moderate Alzheimer's.
Namenda - Approved for moderate to severe Alzheimer's.
Acadia stated that Pimavanserin used with cholinergic drugs has been shown to increase cognition in pre-clinical animal trials. If it proves out in the current ADP trial, that Alzheimers patients taking Pimavanserin with their cholinergic drug, do not lose cognition at the rate seen with current antipsychotics, then it will be another improvement, alongside other safety factors that Pimavanserin has shown. The read-out from the ADP trial will be around the fourth quarter of 2015. Thank you for reading.
No comments:
Post a Comment